MedTrace Logo

Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

NCT04122040 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-10-14

No results posted yet for this study

Summary

roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis

Conditions

  • Quality of Life
  • Respiratory Function Tests

Interventions

DRUG

Roxithromycin 300 MG

Roxithromycin 300 mg oral per day

DRUG

Placebo

Placebo one table oral once dialy

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Kanung Saejiam, MS · Prince of Songkla University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-01
Primary Completion
2011-09-30
Completion
2011-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04122040 on ClinicalTrials.gov